Piper Sandler analyst David Amsellem downgraded the rating on Xeris Pharmaceuticals (XERS – Research Report) to a Hold yesterday, setting ...

Piper Sandler analyst David Amsellem downgraded Xeris Biopharma (XERS) to Neutral from Overweight with an unchanged price target of $3, post ...

Operator: Good day, and welcome to the Third Quarter 2024 Pacira Biosciences Inc. Earnings Conference Call. At this time, all ...

Q3 2024 Earnings Call Transcript November 6, 2024Amphastar Pharmaceuticals, Inc. misses on earnings expectations.

Boston Beer (NYSE:SAM – Free Report) had its price objective boosted by Piper Sandler from $325.00 to $330.00 in a research note issued to investors on Friday morning, Benzinga reports.

Piper Sandler Companies (NYSE:PIPR), a leading investment bank and institutional securities firm, has demonstrated resilience and strategic growth in a dynamic financial landscape. The company's ...

Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Derek Podhaizer as a director and senior research analyst to its energy equity research team.

Good morning and welcome to the Piper Sandler Company's third quarter, 2024 earnings conference call. Today's call is being recorded and will include remarks by Piper Sandler management followed by a ...

Piper Sandler Companies (PIPR) came out with quarterly earnings of $2.57 per share, beating the Zacks Consensus Estimate of $2.53 per share. This compares to earnings of $1.76 per share a year ago.

Piper Sandler Companies (NYSE: PIPR) is a leading investment bank driven to help clients Realize the Power of Partnership®. Securities brokerage and investment banking services are offered in the ...

Piper Sandler raised the firm’s price target on Impinj (PI) to $235 from $225 and keeps an Overweight rating on the shares. The firm notes Impinj reported very strong fundamental results and ...

"By our estimate, Azure IaaS revenue is now 20%-plus lower with a 34% growth profile that could moderate to 33-34% this quarter," said Piper Sandler analysts, led by Brent Bracelin, in an investor ...